Bristol-Myers Squibb Company (BMY) Tax Rate: 24.36%
Is Bristol-Myers Squibb Company’s tax rate high or low?
Bristol-Myers Squibb Company's tax rate of 24.36% is 544% above its 5-year average of 3.78%, near the high end of its 5-year range (-30.91%–24.36%).
The tax rate for Bristol-Myers Squibb Company (BMY) is 24.36%. It is above its 12-month average by 174.48% (8.88%).
BMY Tax Rate Chart
BMY Average Tax Rate Chart
BMY Current vs Average Tax Rate Chart
BMY Tax Rate Metrics
TAX RATE
24.36%
TAX RATE AVG TTM
8.88%
TAX RATE AVG 3Y
10.06%
TAX RATE AVG 5Y
3.78%
TAX RATE AVG 10Y
17.87%
TAX RATE AVG 15Y
16.59%
TAX RATE AVG 20Y
17.85%
CURRENT VS TTM AVG
+174.48%
CURRENT VS 3Y AVG
+142.21%
CURRENT VS 5Y AVG
+543.59%
CURRENT VS 10Y AVG
+36.34%
CURRENT VS 15Y AVG
+46.80%
CURRENT VS 20Y AVG
+36.50%
Bristol-Myers Squibb Company Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Tax Rate FAQ
- What is the tax rate for Bristol-Myers Squibb Company (BMY)?
- The tax rate for BMY stock is 24.36%.
- Is Bristol-Myers Squibb Company's tax rate high or low?
- Bristol-Myers Squibb Company's tax rate of 24.36% is 544% above its 5-year average of 3.78%, near the high end of its 5-year range (-30.91%–24.36%).
- What is the TTM average tax rate for Bristol-Myers Squibb Company (BMY)?
- The TTM average tax rate for BMY stock is 8.88%.
- What is the 3Y average tax rate for Bristol-Myers Squibb Company (BMY)?
- The 3Y average tax rate for BMY stock is 10.06%.
- What is the 5Y average tax rate for Bristol-Myers Squibb Company (BMY)?
- The 5Y average tax rate for BMY stock is 3.78%.
- What is the 10Y average tax rate for Bristol-Myers Squibb Company (BMY)?
- The 10Y average tax rate for BMY stock is 17.87%.
- What is the 15Y average tax rate for Bristol-Myers Squibb Company (BMY)?
- The 15Y average tax rate for BMY stock is 16.59%.
- What is the 20Y average tax rate for Bristol-Myers Squibb Company (BMY)?
- The 20Y average tax rate for BMY stock is 17.85%.
Bristol-Myers Squibb Company Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 24.36% |
| 2024-12-31 | -6.61% |
| 2023-12-31 | 4.74% |
| 2022-12-31 | 17.74% |
| 2021-12-31 | 13.39% |
| 2020-12-31 | -30.91% |
| 2019-12-31 | 30.45% |
| 2018-12-31 | 17.11% |
| 2017-12-31 | 81.00% |
| 2016-12-31 | 23.80% |
| 2015-12-31 | 21.47% |
| 2014-12-31 | 14.78% |
| 2013-12-31 | 10.76% |
| 2012-12-31 | -6.88% |
| 2011-12-31 | 24.65% |
| 2010-12-31 | 25.66% |
| 2009-12-31 | 21.10% |
| 2008-12-31 | 22.82% |
| 2007-12-31 | 22.72% |
| 2006-12-31 | 22.42% |
| 2005-12-31 | 20.21% |
| 2004-12-31 | 34.38% |
| 2003-12-31 | 25.85% |
| 2002-12-31 | 14.16% |
| 2001-12-31 | 3.29% |
| 2000-12-31 | 25.23% |
| 1999-12-31 | 26.54% |
| 1998-12-31 | 24.41% |
| 1997-12-31 | 28.49% |
| 1996-12-31 | 28.98% |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner